Liver Enzymes Abnormalities among Highly Active Antiretroviral Therapy Experienced and HAART Naïve HIV-1 Infected Patients at Debre Tabor Hospital, North West Ethiopia: A Comparative Cross-Sectional Study
Table 2
Clinical and immunological profile of HIV-1 patients at Debre Tabor Hospital, 2013.
Variables
HAART status
On HAART (%)
HAART naive (%)
WHO stage
Stage I
34 (20.7)
97 (59.1)
Stage II
40 (24.4)
44 (26.8)
Stage III
64 (39.0)
19 (11.6)
Stage IV
26 (15.9)
4 (2.4)
OIs
No
150 (91.5)
134 (81.7)
Yes
14 (8.5)
30 (18.3)
BMI (kg/m2)
<18.5
39 (23.8)
40 (24.4)
18.5–25
113 (68.9)
116 (70.7)
>25
12 (7.3)
8 (4.9)
HBV
Negative
156 (95.1)
152 (92.7)
Positive
8 (4.9)
12 (7.3)
HCV
Negative
163 (99.4)
162 (98.8)
Positive
1 (0.6)
2 (1.2)
Regimen
1a
52 (31.7)
—
1b
28 (17.1)
—
1c
40 (24.4)
—
1d
10 (6.1)
—
1e
18 (11.0)
—
1f
16 (9.8)
—
Hepatotoxicity
Grade 1
11 (6.7)
17 (10.4)
Grade 2
6 (3.7)
0
Grade 3
5 (3.0)
1 (0.6)
WHO: World Health Organization; OI: opportunistic infection; BMI: body mass index; HBV: hepatitis B virus; HCV: hepatitis C virus; HAART: highly active antiretroviral therapy; 1a: d4T+3TC+NVP; 1b: d4T+3TC+ EFV; 1c: AZT+3TC+ NVP; 1d: AZT+3TC+EFV; 1e: TDF+3TC+EFV; 1f: TDF+3TC+NVP.
